Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lucentis
Biotech
Outlook's eye disease drug fails to match Lucentis, sinking stock
The biotech brushed off the failure, noting positive details and vowing to seek FDA approval, but investors were less sanguine about the setback.
Nick Paul Taylor
Nov 27, 2024 8:40am
ProQR nabs former Lucentis developer as new CSO
Oct 5, 2020 8:25am
Opthea's VEGF 'trap' combo bests Lucentis alone in wet AMD
Sep 6, 2019 11:24am
Genentech’s first drug implant clears phase 2 study in wet AMD
Jul 26, 2018 2:30pm
Ophthotech completes clean sweep of phase 3 trial flops
Aug 14, 2017 9:00am
Novartis' longer-acting AMD drug matches Eylea in phase 3 trials
Jun 20, 2017 7:39am
